Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
83 hedge funds and large institutions have $136M invested in Melinta Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 13 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 18
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
6% more funds holding
Funds holding: 78 → 83 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $183M → $136M (-$47M)
73% less call options, than puts
Call options by funds: $256K | Put options by funds: $951K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$41.1M |
| 2 |
OH
Oikos Holdings
New York
|
+$26.3M |
| 3 |
FTIOP
Fiduciary Trust International of Pennsylvania
Radnor,
Pennsylvania
|
+$3.94M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.94M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCIM
TIAA CREF Investment Management
New York
|
-$696K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$525K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$512K |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$507K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$405K |
MLNT Hedge Fund Activity: Q1 2018 in Review
83 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q1 2018, worth a combined $136M — down 26% from $183M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MLNT positions and 13 closed out — a net gain of 7 holders — while 28 added to existing stakes and 18 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $41.1M. The largest seller was TIAA CREF Investment Management, cutting an estimated $696K.
- 83 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q1 2018, up from 78 in Q4 2017.
- Funds reported $136M of Melinta Therapeutics, Inc. Common Stock stock for Q1 2018, down 26% quarter-over-quarter.
- 20 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q1 2018 and 13 closed out, a net change of +7 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q1 2018 was Deerfield Management, an estimated $41.1M added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q1 2018 was TIAA CREF Investment Management, an estimated $696K sold.
Based on aggregated 13F filings for Q1 2018.